Table of Contents

1          Executive Summary

2          Introduction

3          Stakeholder and Technology Analysis of Major Pharmaceutical Companies

4          Stakeholder and Technology Analysis of Technology Companies

4.1       Technology Companies with Ig-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies

4.2       Technology Companies with Fc-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies

4.3       Technology Companies with Binder-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies

4.4       Technology Companies with Special T-cell or NK Cell Engaging Bispecific Antibody Technologies

 

5          Pipeline Analysis of T-Cell and NK Cell Engaging Bispecific Antibodies

5.1       Tumor Targeting & Effector Cell Engagement

5.2       Clinical Experience with BCMA-Targeted T-Cell Engaging Bispecific Antibodies

5.3       Clinical Experience with CD33-Targeted T-Cell Engaging Bispecific Antibodies

5.4       Clinical Experience with CD20-Targeted T-cell Redirecting Bispecific Antibodies

5.5       Clinical Experience with CD123-Targeted T-Cell Engaging Bispecific Antibodies

5.6       Clinical Experience with PSMA-Targeted T-Cell Engaging Bispecific Antibodies

5.7       Clinical Experience with Other Solid Tumor Targeted T-Cell Engaging Bispecific Antibodies

5.8       Clinical Experience with Other Blood Cancer Targeted T-Cell Engaging Bispecific Antibodies

5.9       Discontinued Clinical Stage T-Cell Redirecting Bispecific Antibodies

 

6          Sources of Financing and Partnering Deals of Technology Companies

 

  1. Company Profiles

7.1.      Major Pharmaceutical Companies with Bispecific T-Cell or NK Cell Engaging Antibodies

7.2       Technology Companies with Ig-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies

7.3       Technology Companies with Fc-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies

7.4       Technology Companies with Binder-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies

7.5       7.5 Technology Companies with Special Bispecific T-Cell or NK Cell Engaging Antibody Technologies

  • AbbVie
  • Abpro
  • Adimab
  • Affimed Therapeutics
  • Alligator Bioscience
  • Amgen
  • Amphivena Therapeutics
  • Aptevo Therapeutics
  • Arbele
  • Astellas Pharma
  • AstraZeneca
  • BenHealth Biopharmaceuticals
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Crescendo Biologics
  • CytomX Therapeutics
  • Dragonfly Theraputics
  • Eli Lilly
  • GEMoaB Monoclonals
  • Generon
  • Genmab
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • GT Biopharma
  • Harpoon Therapeutics
  • IGM Biosciences
  • Immatics Biotechnologies
  • Immunocore
  • Innate Pharma
  • Inovio Pharmaceuticals
  • Janssen
  • Lava Therapeutics
  • MacroGenics
  • Maverick Therapeutics
  • Merck & Co.
  • Merus
  • Mogam Institute for Biomedical Research (MIBR)
  • Molecular Partners
  • NJCTTQ
  • Novartis
  • Numab
  • Pfizer
  • Pieris Pharmaceuticals
  • PsiOxus Therapeutics
  • Regeneron Pharmaceuticals
  • Revitope Oncology
  • Roche
  • Sanofi
  • Servier
  • Takeda Pharmaceutical Co.
  • TeneoBio
  • VBL Therapeutics
  • Xencor
  • YZY Biopharma
  • Zymeworks

 

8          Technology Profiles

8.1       Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

8.2       Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

8.3       Binder Only-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologie

8.4       Novel „Special“ T-Cell and NK Cell Engaging Bispecific Antibody Technologies

  • ADAPTIR Bispecific, Modular Protein Technology
  • Anticalin Technology
  • ART-Ig Technology
  • Asymmetric head-to-tail 2+1 T-Cell Bispecific (2+1 TCB) IgG antibody platform
  • Azymetric Platform
  • BEAT Technology: Bispecific Engagement by Antibodies based on the T Cell Receptor
  • Biclonics Technology
  • Bispecific IgM Antibodies
  • COBRA Technology
  • CODV-Ig Technology
  • DARPin Multispecifics
  • DNA-Encoded Bi-specific T Cell Engagers (dBiTEs)
  • DuoBody Technolog
  • DVD-Ig Bispecific Antibody Technology
  • GammaDelta T-cell Engager Platform
  • HLE-BiTE Bispecific T Cell Engager Technology
  • Humabody Technology
  • Human Heavy Chain Antibody (UniAb) Platform for Bispecifics
  • ImmunoTherapy Antibody (ITab) technology platform
  • ITE Technology
  • Knobs-into-holes Technology
  • MATCH Technology
  • MultiMab Technology with TetraBi Format
  • NK Cell Engager (NKCE) Technology
  • ROCK Platform: Redirected Optimized Cell Killing
  • RUBY Technology
  • T cell Engaging Antibody Circuits (TEACs)
  • T cell-engaging Bispecific Probody Technology
  • T-Cell Engaging Full Length Bispecific Antibody Platform
  • TCER: Bispecific T-cell Engaging Receptor Molecules
  • TCR-based ImmTAC Technology
  • TriKE and TetraKE Technologies
  • TriNKET Technology
  • TriTAC & ProTriTAC Technologies
  • Tumor-Specific Immuno-Gene Therapy (T-SIGn)
  • Veloci-Bi Technology
  • XmAb Bispecific Fc Technology
  • YBody Bispecific Antibody Technology

 

9          Drug and Drug Candidate Profiles

9.1.1    A-319

9.1.2    A-337

9.1.3    ABBV-428

9.1.4    ABP-100

9.1.5    ABP-110

9.1.6    ABP-150

9.1.7    AFM13

9.1.8    AFM14

9.1.9    AFM26

9.1.10  ALG.APV-527

9.1.11  AMG 160

9.1.12  AMG 212

9.1.13  AMG 330

9.1.14  AMG 420

9.1.15  AMG 424

9.1.16  AMG 427

9.1.17  AMG 562

9.1.18  AMG 596

9.1.19  AMG 673

9.1.20  AMG 701

9.1.21  AMG 757

9.1.22  AMV564

9.1.23  Anti-FLT3

9.1.24  Anti-ROR1

9.1.25  APVO436

9.1.26  ARB-201

9.1.27  Blincyto

9.1.28  BMS-986277

9.1.29  CB307

9.1.30  CC-93269

9.1.31  ERY974

9.1.32  GBR1302

9.1.33  GBR1342

9.1.34  GBR1372

9.1.35  GEM3PSCA

9.1.36  GEM333

9.1.37  GEN3013

9.1.38  HPN217

9.1.39  HPN328

9.1.40  HPN424

9.1.41  HPN536

9.1.42  IGM2323

9.1.43  IMC-C103C

9.1.44  IMC-F106C

9.1.45  IMCgp100

9.1.46  IMCnyeso

9.1.47  IPH61

9.1.48  JNJ-63709178

9.1.49  JNJ-6389808

9.1.50  JNJ-64007957

9.1.51  JNJ-64407564

9.1.52  JNJ-67571244

9.1.53  M701

9.1.54  M802

9.1.55  MCLA-117

9.1.56  MCLA-145

9.1.57  MG1122

9.1.58  MGD006

9.1.59  MGD007

9.1.60  MGD009

9.1.61  MGD014

9.1.62  MO0310

9.1.63  ND021

9.1.64  NG-641

9.1.65  OXS-1615

9.1.66  OXS-3550

9.1.67  OXS-C3550

9.1.68  PF-06671008

9.1.69  PF-06863135

9.1.70  PRS-342

9.1.71  REGN1979

9.1.72  REGN4018

9.1.73  REGN5458

9.1.74  RG6026

9.1.75  RG6160

9.1.76  RG6194

9.1.77  RG7802

9.1.78  RG7827

9.1.79  RG7828

9.1.80  SAR440234

9.1.81  TNB-383B

9.1.82  TNB-486

9.1.83  TNB-585

9.1.84  TSA(1)-CD28 & TSA(2)-CD28

9.1.85  VB-600

9.1.86  XmAb13676

9.1.87  XmAb14045

9.1.88  XmAb18087

9.1.89  XmAb23104

9.1.90  Y111

 

10        References